- Home
- AR vs EXEL Comparison
AR vs EXEL Comparison
Compare AR & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AR
- EXEL
- Stock Information
- Founded
- AR 2002
- EXEL 1994
- Country
- AR United States
- EXEL United States
- Employees
- AR N/A
- EXEL N/A
- Industry
- AR Oil & Gas Production
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AR Energy
- EXEL Health Care
- Exchange
- AR Nasdaq
- EXEL Nasdaq
- Market Cap
- AR 8.5B
- EXEL 9.7B
- IPO Year
- AR 2013
- EXEL 2000
- Fundamental
- Price
- AR $33.18
- EXEL $34.65
- Analyst Decision
- AR Buy
- EXEL Buy
- Analyst Count
- AR 18
- EXEL 18
- Target Price
- AR $32.56
- EXEL $31.72
- AVG Volume (30 Days)
- AR 3.9M
- EXEL 2.5M
- Earning Date
- AR 10-30-2024
- EXEL 10-29-2024
- Dividend Yield
- AR N/A
- EXEL N/A
- EPS Growth
- AR N/A
- EXEL 441.02
- EPS
- AR 0.15
- EXEL 1.55
- Revenue
- AR $4,272,370,000.00
- EXEL $2,081,598,000.00
- Revenue This Year
- AR N/A
- EXEL $20.53
- Revenue Next Year
- AR $17.29
- EXEL $1.54
- P/E Ratio
- AR $226.62
- EXEL $22.42
- Revenue Growth
- AR N/A
- EXEL 17.31
- 52 Week Low
- AR $20.10
- EXEL $19.20
- 52 Week High
- AR $36.28
- EXEL $36.60
- Technical
- Relative Strength Index (RSI)
- AR 71.21
- EXEL 67.59
- Support Level
- AR $30.16
- EXEL $33.82
- Resistance Level
- AR $32.17
- EXEL $36.49
- Average True Range (ATR)
- AR 1.07
- EXEL 0.82
- MACD
- AR 0.46
- EXEL -0.25
- Stochastic Oscillator
- AR 96.54
- EXEL 40.18
About AR Antero Resources Corporation
Antero Resources, based in Denver, engages in the exploration for and production of natural gas and natural gas liquids in the United States and Canada. At the end of 2023, the company reported proven reserves of 18.1 trillion cubic feet of natural gas equivalent. Production averaged approximately 3,483 million cubic feet of equivalent a day in 2023 at a ratio of 37% liquids and 63% natural gas.
About EXEL Exelixis Inc.
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.